BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26919105)

  • 1. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
    Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
    Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
    De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
    Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of osteopontin and vascular endothelial growth factor in correlation with angiogenesis in monoclonal gammopathy of undetermined significance and multiple myeloma.
    Babarović E; Valković T; Budisavljević I; Balen I; Štifter S; Duletić-Načinović A; Lučin K; Jonjić N
    Pathol Res Pract; 2016 Jun; 212(6):509-16. PubMed ID: 26997492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
    Desantis V; Frassanito MA; Tamma R; Saltarella I; Di Marzo L; Lamanuzzi A; Solimando AG; Ruggieri S; Annese T; Nico B; Vacca A; Ribatti D
    Ann Hematol; 2018 Jul; 97(7):1251-1258. PubMed ID: 29589107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide restrains motility and overangiogenic potential of bone marrow endothelial cells in patients with active multiple myeloma.
    De Luisi A; Ferrucci A; Coluccia AM; Ria R; Moschetta M; de Luca E; Pieroni L; Maffia M; Urbani A; Di Pietro G; Guarini A; Ranieri G; Ditonno P; Berardi S; Caivano A; Basile A; Cascavilla N; Capalbo S; Quarta G; Dammacco F; Ribatti D; Vacca A
    Clin Cancer Res; 2011 Apr; 17(7):1935-46. PubMed ID: 21307145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets.
    Berardi S; Caivano A; Ria R; Nico B; Savino R; Terracciano R; De Tullio G; Ferrucci A; De Luisi A; Moschetta M; Mangialardi G; Catacchio I; Basile A; Guarini A; Zito A; Ditonno P; Musto P; Dammacco F; Ribatti D; Vacca A
    Oncogene; 2012 May; 31(18):2258-69. PubMed ID: 21963844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombopoietin Promotes Angiogenesis and Disease Progression in Patients with Multiple Myeloma.
    Lamanuzzi A; Saltarella I; Frassanito MA; Ribatti D; Melaccio A; Desantis V; Solimando AG; Ria R; Vacca A
    Am J Pathol; 2021 Apr; 191(4):748-758. PubMed ID: 33516787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
    Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
    J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?
    Saltarella I; Frassanito MA; Lamanuzzi A; Brevi A; Leone P; Desantis V; Di Marzo L; Bellone M; Derudas D; Ribatti D; Chiaramonte R; Palano MT; Neri A; Mariggiò MA; Fumarulo R; Dammacco F; Racanelli V; Vacca A; Ria R
    Neoplasia; 2019 Jan; 21(1):93-105. PubMed ID: 30529074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Endothelial Cells and Fibroblasts in Multiple Myeloma Angiogenic Switch.
    Ribatti D; Vacca A
    Cancer Treat Res; 2016; 169():51-61. PubMed ID: 27696258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma.
    Vacca A; Scavelli C; Serini G; Di Pietro G; Cirulli T; Merchionne F; Ribatti D; Bussolino F; Guidolin D; Piaggio G; Bacigalupo A; Dammacco F
    Blood; 2006 Sep; 108(5):1661-7. PubMed ID: 16684957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
    Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
    Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIF-1α of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target.
    Ria R; Catacchio I; Berardi S; De Luisi A; Caivano A; Piccoli C; Ruggieri V; Frassanito MA; Ribatti D; Nico B; Annese T; Ruggieri S; Guarini A; Minoia C; Ditonno P; Angelucci E; Derudas D; Moschetta M; Dammacco F; Vacca A
    Clin Cancer Res; 2014 Feb; 20(4):847-58. PubMed ID: 24297864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epo is involved in angiogenesis in human glioma.
    Nico B; Annese T; Guidolin D; Finato N; Crivellato E; Ribatti D
    J Neurooncol; 2011 Mar; 102(1):51-8. PubMed ID: 20614229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
    Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
    Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erythropoietin accelerates tumor growth through increase of erythropoietin receptor (EpoR) as well as by the stimulation of angiogenesis in DLD-1 and Ht-29 xenografts.
    Tankiewicz-Kwedlo A; Hermanowicz J; Surażynski A; Rożkiewicz D; Pryczynicz A; Domaniewski T; Pawlak K; Kemona A; Pawlak D
    Mol Cell Biochem; 2016 Oct; 421(1-2):1-18. PubMed ID: 27543111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
    Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
    Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
    Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
    Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts.
    Doleschel D; Mundigl O; Wessner A; Gremse F; Bachmann J; Rodriguez A; Klingmüller U; Jarsch M; Kiessling F; Lederle W
    J Nucl Med; 2012 Feb; 53(2):304-11. PubMed ID: 22228796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.